随机、多中心、双盲、万古霉素对照研究,以评估乙醇锁液治疗因凝固酶阴性葡萄球菌引起的植入式静脉通路端口感染的疗效 (Etha-LOCK)
Implantable venous access port infections are mainly due to coagulase negative staphylococci and may be managed by antibiotic lock therapy with retention of the port. Most of the time a vancomycin lock is used. Experimental data show that vancomycin may be poorly effective in eradicating the staphylococcal biofilm in the port. Another disadvantage of Vancomycin-containing lock solution is the occurrence of resistant organisms and the risk of catheter occlusion. Ethanol-containing lock solution is highly effective in vitro and does not expose to the risk of emergence resistance.
研究概览
地位
详细说明
Type of study: multi-center, randomized, double-blind, parallel-group, controlled clinical trial.
Number of centers: 9 French centers in Auvergne and Rhône-Alpes regions
Medical product Ethanol 40% + Enoxaparine 400UI/ml Versus Vancomycin 5 mg/ml + Héparine 2500UI/ml
Patients
Patients eligible for inclusion will be randomized to one of the two groups:
- Experimental group: 90 patients will receive 10 injections of ethanol lock solution in implantable venous access port during the first 10 days of the study.
- Control group: 90 patients will receive 10 injections of vancomycin lock solution in implantable venous access port during the first 10 days of the study.
- For each group, in case of bacteraemia, the lock therapy is associated with a systemic antibiotic therapy using another venous line and optimized by a specialist in infectious diseases.
Study Performance
Patients will be assessed at baseline D0, 3 days (D3), 10 days (D10), 14 weeks (W14) after D0 as follows:
Visit 1 (D0 - baseline):
- Signature of an informed consent form.
- Demographic and clinical characteristics (sex, age, disease associated with implantable venous access port, implantable venous access port infection data, bacteraemia data)
Days 1 to 10
- Injection of ethanol or vancomycin lock solution in implantable venous access port
- Ethanolemia 30 minutes after injection, on first day
- Side effects evaluation
Visit 2 (D3) and Visit 3 (D10)
- Side effects evaluation
- Blood culture
- Bacteraemia data (antibiotic therapy modification)
Phone contact each week from week 2 to week 13
End Visit (W14)
- Side effects evaluation
- Blood culture
- Bacteraemia data (antibiotic therapy modification)
研究类型
注册 (实际的)
阶段
- 不适用
联系人和位置
学习地点
-
-
-
Clermont-Ferrand、法国、63003
- CHU Clermont-Ferrand
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Man or woman from 18 years old
- With probable or definite implantable venous access port infection
- With or without bacteraemia
- Infection due to coagulase-negative staphylococci (except for lugdunensis Staphylococci)
- Blood culture results available within 48 hours before inclusion
- With health insurance
Exclusion Criteria:
- Pregnant or breastfeeding woman
- Allergy to ethanol
- Patient with prosthetic cardiac valve
- Necessity of venous access port withdrawal
- Prior infection on the same venous access port
- Patients under supervision or (legal) guardianship
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:双倍的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Experimental group
90 patients will receive 10 injections of ethanol lock solution in implantable venous access port during the first 10 days of the study. |
|
|
其他:control group
90 patients will receive 10 injections of vancomycin lock solution in implantable venous access port during the first 10 days of the study |
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
锁固液治疗完成后 12 周恢复
大体时间:在第 12 周
|
在第 12 周
|
|
在植入式静脉通路端口使用结束之前没有并发症的有利发展
大体时间:在第 12 周
|
在第 12 周
|
|
在植入式静脉通路端口撤回之前没有并发症的有利进展
大体时间:在第 12 周
|
在第 12 周
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
外周血和端口血培养阴性
大体时间:在第 3 天和第 10 天
|
在第 3 天和第 10 天
|
|
因港口感染而死亡
大体时间:在第 1 天
|
在第 1 天
|
|
植入式静脉通路端口退出率
大体时间:在第 1 天
|
在第 1 天
|
|
机械并发症发生率
大体时间:在第 1 天
|
在第 1 天
|
|
血液酒精浓度
大体时间:第一次锁固液处理后 30 分钟
|
第一次锁固液处理后 30 分钟
|
|
副作用评估
大体时间:在第 1 天
|
在第 1 天
|
合作者和调查者
合作者
调查人员
- 首席研究员:Olivier LESENS、University Hospital, Clermont-Ferrand
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.